Asundexian for Secondary Stroke Prevention
The New England Journal of Medicine
•
April 16, 2026
Asundexian lowers recurrent ischemic stroke risk
Adding asundexian to antiplatelet therapy reduced recurrent ischemic stroke without increasing major bleeding. *Randomized double-blind placebo-controlled trial; Level 1b (OCEBM).
- Level of evidence
- Level 1b (OCEBM)
- DocG quality score
- 7.9 / 10
Read the full summary free
Patients, intervention, outcomes, results, and clinical applicability in about 300 words — plus new summaries in your inbox 3× per week.
Sign in with Google
